Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
23.1M
-
Shares change
-
-1.06M
-
Total reported value, excl. options
-
$333M
-
Value change
-
-$15.4M
-
Number of buys
-
40
-
Number of sells
-
-36
-
Price
-
$14.42
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q3 2022
101 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2022.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.1M shares
of 45.1M outstanding shares and own 51.15% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.9M shares), Polar Capital Holdings Plc (2.53M shares), Sofinnova Investments, Inc. (2.19M shares), ALLIANCEBERNSTEIN L.P. (2.15M shares), WELLINGTON MANAGEMENT GROUP LLP (1.95M shares), VANGUARD GROUP INC (1.92M shares), STATE STREET CORP (1.92M shares), FMR LLC (1.38M shares), GEODE CAPITAL MANAGEMENT, LLC (633K shares), and BIOIMPACT CAPITAL LLC (444K shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.